Key Takeaways Most GLP patches are marketing, not medicine: there is no strong clinical evidence that a skin patch delivers GLP-1 level weight loss on its own
This strategy was used for the STEP 1 trial of semaglutide 2.4 mg [38]
Moreover, the ability of GLP-1 signaling to interact with alcohol-related effects also appears to hold true in the clinical situation, the findings for which are reviewed herein
Why oral semaglutide is different Oral semaglutide (Rybelsus) presents a unique problem
I naturally tend to eat a later breakfast around 10am, but I make up for it by having a snack in the evenings, so that doesnt really count
Diabetes Obes Metab 25(1):5667 Rosenstock J, Wysham C, Frias JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial